Researchers from Peking University and Bristar Immunotech Ltd. recently presented the development of a synthetic T-cell receptor and antigen receptor-T (STAR-T) cell therapy targeting leukocyte immunoglobulin-like receptor B4 (LILRB4) for acute myeloid leukemia (AML).